Amarin Corp ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 28 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Total Net Revenue Quarterly45.1M
U.S. VASCEPA Net Product Revenue Quarterly35.6M
Aggregate Cash and Investments Quarterly307.8M
Global Restructuring Annual Cost Savings Annually31M
Watch Items
- European VAZKEPA commercialization expansion by partner Recordati S.p.A.Trigger: Launch progress across 10 initial European countries and subsequent geographic expansionAction: Monitor quarterly European product revenue and licensing/royalty revenue streams
- U.S. VASCEPA market share defense against generic competitionTrigger: Maintenance of leading market share and stable prescription volumes throughout 2026Action: Track industry prescription data and exclusive status with national pharmacy benefit managers (PBMs)
Research as of 20 Jun 2026